Therapeutic Potential of Ion Provider Antibiotics in Ovarian Most cancers: Me

Introduction

Ovarian most cancers has lengthy been the deadliest malignant tumor amongst gynecological tumors.^1–5 Amongst gynecological tumors, ovarian most cancers has traditionally been the deadliest kind of most cancers.⁶ The gold customary for treating ovarian most cancers has been cytoreductive surgical procedure plus systemic chemotherapy because the mid-Nineteen Nineties.^6–8 Regardless of this, there has not been a noticeable enchancment within the 5-year ovarian most cancers survival charge throughout the beforehand talked about 20 years.^9,10 The principle motive for the low affected person survival charge is the refined signs of ovarian most cancers, that are normally detected solely after the illness has superior. Moreover, most sufferers will finally face a recurrence of the illness, though many obtain full medical remission after preliminary therapy. Sufferers with ovarian most cancers are experiencing shorter durations of remission or illness stabilization attributable to an rising variety of chemotherapy regimens that result in multidrug resistance. This finally ends in dying.^2,7,11 The principle components affecting the prognosis of ovarian most cancers embrace metastasis, invasion, and tumor cell resistance to chemotherapy medication. These traits are intently related to the recurrence of ovarian most cancers. Each carboplatin and paclitaxel, that are generally utilized in medical apply, have important killing results on a variety of tumor varieties in the mean time,^12–14 many research have demonstrated that completely different tumor varieties are inclined to growing resistance to both cisplatin or paclitaxel,^15–17 suggesting that these two first-line chemotherapy medication might not be as efficient at stopping most cancers cell metastasis, invasion, and resistance. Subsequently, to enhance the prognosis for ovarian most cancers sufferers, it’s important to establish and develop candidate medication that may considerably decrease remedy resistance and cut back most cancers cell invasion and metastasis. In recent times, analysis on anti-tumor medication has been increasing steadily, and focused remedy has made important progress, equivalent to with bevacizumab and PARP inhibitors. In a Section III trial involving 806 sufferers with superior ovarian most cancers, Olaparib mixed with bevacizumab improved progression-free survival in comparison with placebo plus bevacizumab in sufferers with tumors constructive for homologous-recombination deficiency.¹⁸ Moreover, some antibiotic medication have proven promising anti-tumor exercise and potential. The investigation of latest anti-tumor medication derived from these brokers has opened new avenues for most cancers therapy analysis.¹⁹

First utilized in 1967, the time period “ion service” describes a molecule’s capability to bind metallic ions and make it simpler for them to go via cell membranes.²⁰ This physicochemical property makes polyether ion carriers a useful software for learning cation transport mechanisms. The Gram(+) micro organism of the genus Streptomyces produce ion service antibiotics, a category of greater than 120 structurally associated fat-soluble medication with related constructing blocks and a shared mode of motion. Polyether ion service antibiotics show a broad vary of organic actions, together with antiviral, antifungal, antibacterial, and antiparasitic results, and these medication have been initially extensively used as feed components in industrial animal husbandry. The antimicrobial bioactivity of ion-carrier antibiotics is intently linked to the traits of their ion carriers. Initially, these drugs have been regularly added to feed in industrial animal husbandry. The antibacterial motion of ion-carrier antibiotics is functionally linked to the properties of their ion carriers. They’ll selectively bind metallic cations, primarily alkaline cations, and switch them from the extracellular surroundings into the cell via the biofilm, the place the transported cations are liberated.²¹ In medical apply, ion service antibiotics equivalent to monensin,^22,23 salinomycin,^24,25 nigericin,^26,27 doxycycline,^28,29 and ivermectin^30,31 are regularly utilized. Ionophore antibiotics have been proven in research to have anti-tumor properties when used to deal with a wide range of malignant tumors,³² though analysis on ovarian most cancers stays comparatively insufficient. This text discusses the current advances in ion service antibiotic analysis associated to ovarian most cancers.

The Anti-Tumor Properties of Ion-Provider Antibiotics

Inhibit Tumor Cell Proliferation

It has been discovered that ion service antibiotics inhibit the expansion and multiplication of many tumor cell varieties; as an illustration, monensin prevents the expansion of assorted tumor cell varieties. Solely 5% of sufferers with pancreatic ductal adenocarcinoma (PDAC) survive for 5 years. In vitro, monensin induced apoptosis in pancreatic most cancers cell traces PANC-1 and MiaPaCa-2 by suppressing their progress and cell cycle development. And prevented PDAC xenograft tumors from rising in vivo.³³ Glioblastoma is a tumor with a horrible prognosis. Monensin not solely prevents glioblastoma cells from proliferating and capillary formation in glioblastoma endothelial cells in vitro, but it surely additionally prevents tumor progress in glioblastoma cells mouse xenografts in vivo.³⁴ When it comes to feminine morbidity, breast most cancers ranks as the primary malignant tumor. Research have demonstrated that monensin can dramatically cut back the expansion of breast most cancers cells, pace up apoptosis, upregulate the expression of genes intently linked to apoptosis, like Bax2, Caspase3, and Caspase7, and downregulate the expression of anti-apoptosis Bcl-2. And stop breast most cancers cells from growing tumors.²² Moreover, analysis on prostate most cancers has demonstrated that monensin disrupts Ca²⁺ homeostasis and induces the discharge of reactive oxygen species from mitochondria. Monensin additionally stops the cell cycle within the G1 part and lowers the survival charge of the prostate cell line PC-3.³⁵ In human lymphoma cell traces, SNU-C1 colon most cancers cells, and NCI-H929 myeloma cells, monensin alters mitochondrial transmembrane potential and induces G1 and/or G2-M part arrest, which has antiproliferative results.^36,37 As well as, monensin also can inhibit the survival charge of lung most cancers cells.³⁸

The antibiotic salinomycin, a polyether ion service, can kill tumor stem cells effectively.³⁹ As well as, salinomycin can induce apoptosis in lots of tumor cells. The disruption of the Wnt/β-catenin signaling pathway is intently associated to tumor stem cell survival and metastasis. The formation of stem cells relies upon closely on the Wnt/β-linker signaling system, and most cancers drugs that focus on this pathway could act whether it is abnormally activated (Determine 1). Analysis has proven that salinomycin inhibits Wnt1-induced signaling at nanomolar concentrations and promotes β-catenin degradation at micromolar concentrations, thereby blocking downstream activator-induced Wnt signaling. The Wnt/β-catenin signaling system could also be inhibited by salinomycin, which can consequence within the dying of tumor stem cells.⁴⁰ Salinomycin was discovered to extend β-conjugated protein degradation at micromolar doses whereas inhibiting Wnt1-induced signaling at nanomolar concentrations, thereby blocking downstream activator-induced Wnt signaling. Consequently, completely different doses of salinomycin can inhibit Wnt signaling via distinct mechanisms. In subsequent experiments, salinomycin efficiently induced apoptosis in malignant lymphocytes, whereas excessive concentrations of salinomycin didn’t induce apoptosis in peripheral blood mononuclear cells beneath the identical situations. It was demonstrated that salinomycin was selectively cytotoxic to tumor cells reliant on Wnt signaling.⁴¹

Present research have demonstrated that monensin can stop completely different tumor cells from spreading and invading different areas. Within the discipline of breast most cancers, research have proven that monensin can inhibit the migration and invasion of breast most cancers cells, and may inhibit the expression of matrix metalloproteinases-2 and −9, which is intently associated to metastasis and invasion in cells. It’s speculated that the mechanism of tumor suppression could also be achieved by down-regulating the UBA2 gene.22 Research on colorectal most cancers have demonstrated that monensin can stop the expression of Wnt/β-catenin in colorectal most cancers cells,⁴² Attributable to Wnt/β-catenin being one of many core components regulating the epithelial-mesenchymal transition (EMT) pathway,^43,44 the EMT course of is an element that straight determines the power of cells to metastasize and invade,^45–47 due to this fact, it may be inferred that monensin can additional inhibit the metastasis and invasion means of colon most cancers cells by suppressing the expression stage of β-catenin. As well as, primarily based on the shut relationship between the EMT pathway and most cancers metastasis and drug resistance, the EMT-selective compounds have been screened by a high-content screening scheme of cell imaging. It was discovered that monensin has EMT selectivity and may induce apoptosis, cell cycle arrest, and reactive oxygen species launch.⁴⁸ Tumor stem cells or stem cell-like tumor cells have excessive invasion and metastasis means. Monensin additionally has a superb inhibitory impact on tumor stem cells.^23,49 The excessive metastasis and invasion traits of most cancers stem cells and stem cell-like tumor cells are additionally associated to the EMT course of.^50,51

Human colon most cancers cells handled with salinomycin exhibit decreased colony-forming capability and cell motility, indicating that salinomycin not solely selectively targets colon most cancers stem cells but additionally inhibits colon most cancers cell invasion and migration.⁵² Salinomycin decreases the viability of glioblastoma cells, in accordance with research.⁵³ Mycamycin targets the extracellular signal-regulated kinase-cyclin D1 and p38 pathways, respectively, to forestall endothelial cell migration and proliferation. This reduces the stimulatory affect of vascular endothelial progress issue. Moreover, inostamycin possesses anti-invasive and anti-proliferative properties.⁵⁴ The vast majority of cancer-related deaths are brought on by invasion and metastasis, so this may present new insights into the therapy of tumors.

Cut back Tumor Cell Resistance

Throughout chemotherapy, drug resistance is a standard medical challenge for most cancers sufferers. Thus, discovering novel drugs for most cancers therapy is a major problem, and polyether ion service antibiotics are potential candidates. These ion-carrier antibiotics can reverse multidrug resistance in human most cancers and enhance chemosensitivity to most cancers cells. In an effort to seek out potential new therapy targets, research have checked out how polyether ion service antibiotics have an effect on colchicine resistance in human most cancers multidrug-resistant KB-C410 cells. The findings of those investigations demonstrated {that a} vary of polyether ion service antibiotics would possibly overcome colchicine resistance. Lethalomycin had good efficacy, rising the cytotoxicity of colchicine in KB-C700 cells by roughly one-fold at a dosage of 4 μg/m.⁵⁵

Salinomycin can lower the emergence of drug resistance in most cancers cells handled with anticancer drugs equivalent to vincristine, paclitaxel, docetaxel, and colchicine. Moreover, salinomycin made most cancers cells extra inclined to the apoptotic results of adriamycin and etoposide. Salinomycin has been proven to extend DNA harm and decrease the quantity of the anti-apoptotic protein p21 in most cancers cells, rising their vulnerability to the consequences of etoposide and adriamycin.⁵⁶ The mixture of salinomycin with different chemotherapeutic brokers will end in much less resistance in glioblastoma cells.⁵³

The antibiotic natamycin, a polyether ion service, additionally lowered the multidrug resistance exhibited by KB-C4 human most cancers cells. Inostamycin elevated periwinkle accumulation in a dose-dependent manner in multidrug-resistant KB-C4 cells. The lively efflux of periwinkle from KB-C4 cells was blocked by inostamycin, however the vincristine efflux from KB-3-1 cells was not affected. At a focus of 1 μg/mL natamycin, the 4-hour enhance in periwinkle accumulation in KB-C4 cells was roughly double. Though natamycin bonded to the KB plasma membrane irreversibly, in accordance with mechanistic investigations, the binding capability didn’t correspond with the degrees of P-glycoprotein within the three KB cell traces, and natamycin may irreversibly bind to the plasma membrane through phosphatidylethanolamine, thereby irreversibly inhibiting P-glycoprotein.^57,58 When inostamycin and paclitaxel have been administered collectively, the capability to trigger apoptosis in Ms-1 cells was enhanced. MS-1 cells handled with natamycin required much less paclitaxel to induce apoptosis. Consequently, inostamycin is an efficient therapy for small-cell lung most cancers when used at the side of paclitaxel.⁵⁹ Nonetheless, in each KB parental and KB/multidrug-resistant cells, monensin was a powerful inhibitor of proliferation. Monensin intervention boosted the intracellular accumulation of Adriamycin in KB/multidrug-resistant cells by roughly two to a few instances, however the phenomenon was absent in KB parental cells. Moreover, monensin dramatically decreased the efflux of Adriamycin from KB/multidrug-resistant cells. These findings suggest that monensin could reverse multidrug resistance by selling drug transport and, in flip, rising DNA harm in cells. The idea that monensin works straight on P-glycoprotein in multidrug-resistant cells is supported by mechanistic investigations that confirmed it decreased drug efflux however didn’t change the subcellular distribution of zorubicin.^60–62

Quite a lot of antibiotics with antitumor exercise can inhibit the resistance of tumor cells to chemotherapeutic medication; for instance, salinomycin can block NF-κB nuclear translocation in cisplatin-resistant breast most cancers cells, down-regulate the expression of Survivin, XIAP, and Bcl-2 genes, that are positively correlated with cell survival, and additional inhibit the proliferation and metastasis of cisplatin-resistant breast most cancers cells;⁶³ Nigericin inhibits the Wnt/β-catenin signaling system, which lowers the lifespan of lung malignancies and multidrug-resistant lung most cancers cells;⁶⁴ By binding to the extracellular area of the epidermal progress issue receptor (EGFR) on tumor cell membranes, ivermectin can inhibit the ERK/AKT/NF-κB signaling pathway, which is intently linked to the expansion and metastasis of tumor cells and additional inhibit the expression of P-glycoprotein, which has the perform of maintaining medication out of the cell. Thereby overcoming some tumor cells’ therapy resistance.⁶⁵ In drug-resistant pancreatic most cancers cell traces, research have demonstrated that monensin will increase apoptosis and inhibits cell proliferation, cell cycle development, and cell metastasis, most certainly through reducing tumor cells’ ranges of EGFR expression.³³ In one other research, non-small cell lung most cancers (NSCLC) cells have been constructed with EGFR-tyrosine kinase inhibitor resistance induced by modulation of the EMT pathway. The addition of monensin markedly inhibited the EMT course of in drug-resistant lung most cancers cells, and the EGFR-tyrosine kinase inhibitor restored the inhibition of drug-resistant lung most cancers cells. Development and apoptosis-promoting results on drug-resistant lung most cancers cells.⁶⁶ One other research confirmed that monensin was capable of restore the sensitivity of tumor necrosis factor-related apoptosis-induced ligand (TRAIL)-resistant glioma cells to the apoptosis-inducing results of TRAIL, probably by inducing the endoplasmic reticulum stress response. Up-regulation of dying receptor 5 and down-regulation of Fas-related dying domain-like interleukin-1β-converting enzyme inhibitory protein elevated the effectivity of tumor cells in receiving and processing apoptotic alerts.⁶⁷

Ion service antibiotics can straight induce apoptosis in most cancers cells, stopping tumor invasion and progress. When mixed with different anticancer medication, they may also help overcome drug resistance and improve the effectiveness of remedy. Subsequently, ion service antibiotics have sturdy anti-tumor properties, that are useful for managing tumor problems and growing new anti-tumor medication, exhibiting broad potential for analysis and improvement.

The Inhibitory Impact of Ion Provider Antibiotics on Ovarian Most cancers

Monensin

Monensin is a pure lipid-soluble bioactive ion service produced by Streptomyces cinnamonensis, with a molecular weight of 670 and a components of C36H61O11, whose antimicrobial exercise is mediated by its perform of exchanging Na+ and Okay+ ions throughout mobile membranes, which disrupts the ionic gradient and alters mobile physiology. The US Meals and Drug Administration has approved monensin as a veterinary antibiotic for the therapy of coccidiosis.^68–70 Along with its use as a veterinary drug, monensin reveals broad-spectrum exercise in opposition to human conditionally pathogenic micro organism, viruses, fungi, and parasites in each drug-sensitive and drug-resistant strains.⁶⁸ One other research discovered that monensin sodium salt could possibly deal with new coronavirus infections by blocking SARS-CoV-2S protein-mediated cell fusion.⁷¹ An increasing number of research are discovering that monensin has anti-tumor exercise.

Monensin inhibits the proliferation of assorted ovarian cells to various levels and principally capabilities throughout the G1/S part of the cell cycle. It additionally inhibits ovarian cell invasion and migration, which has a powerful correlation with the expression of key kinases like MEK and ERK in addition to signaling molecules linked to EMT.^72,73 Monensin attenuates the exercise of MEK1 by enhancing SUMO1 modification of MEK1 and inhibiting its activation, which in flip negatively regulates the ERK pathway and finally inhibits cell overgrowth.⁷⁴ Moreover, Deng et al investigated the potential of the antibiotic monensin as an anti-ovarian most cancers remedy utilizing the human ovarian most cancers traces HeyA8 and SKOV3. It has been found that monensin effectively induces apoptosis and inhibits the expansion, migration, and cell cycle development of human ovarian most cancers cells. That is principally as a result of monensin can decrease the expression of EGFR in ovarian most cancers cells and inhibit cancer-related pathways equivalent to Elk1/SRF, AP1, NFκB, and STAT. When mixed with oxaliplatin and EGFR inhibitors, monensin can cease the expansion of ovarian most cancers cells and trigger them to endure apoptosis.⁷⁵

Moreover stopping tumor cells from proliferating, migrating, and invading, ovarian most cancers medication should additionally possess sturdy resistance, which is a serious impediment to utilizing conventional chemotherapy brokers like paclitaxel and platinum.^76–79 Monensin can inhibit the proliferation, metastasis, and different tumor cell options of a couple of kind of drug-resistant cells,^33,66 and in addition selectively inhibits the expansion of tumor cells with an lively EMT course of,²³ and it’s also efficient in opposition to drug-resistant cells susceptible to drug resistance with the traits of a tumor stem cell,^23,49 so monensin can also play a extra important function in overcoming most cancers cells’ resistance. Thus, monensin could possibly fulfill the necessity for efficient drug performance within the therapy of ovarian most cancers.

Salinomycin

Streptomyces albus is the supply of the monocarboxylic polyether antibiotic salinomycin. Initially, it was employed as an agricultural antimicrobial agent for poultry and diet. In animal trials, Gupta et al notably inhibited breast most cancers stem cells by lowering tumor dimension and boosting apoptosis and necrosis, proving for the primary time that salinomycin is the best remedy in opposition to breast most cancers stem cells.³⁹ Present knowledge point out that salinomycin can goal cells that resemble most cancers stem cells in a wide range of human malignancies,³⁹ inflicting results together with apoptosis induction, suppression of tumor cell proliferation, angiogenesis, autophagy, and so on., in addition to concentrating on the Wnt and EMT pathways to forestall tumor invasion and migration.^80–87 As an anticancer agent, salinomycin has important therapeutic potential.

By blocking the Wnt/β-catenin pathway and stopping EMT from forming, salinomycin decreases cell invasion and migration and prevents the expansion of epithelial ovarian most cancers cells.⁸⁸ Fuat Kaplan et al handled ovarian most cancers cells and ovarian epithelial cells with eight numerous concentrations of salinomycin, together with 0.1, 1, and 40 μM, as a way to additional look at the apoptotic and cytotoxic results of salinomycin on the human ovarian most cancers cell line (OVCAR-3) after which cultured them individually. It was found that incubating human OVCAR-3 cells with 0.1 μM salinomycin for twenty-four hours may set off apoptosis and kill 40% of the most cancers cells by up-regulating the expression of the apoptotic Bax gene, down-regulating the expression of the anti-apoptotic Bcl-2 gene, and rising the expression of lively caspase-3 protein, whereas not affecting regular cells⁸⁹ (Determine 2). Moreover, salinomycin, a doable chemotherapeutic drug for the therapy of cisplatin-resistant ovarian most cancers, could cause the dying of cisplatin-resistant ovarian most cancers cells by blocking Akt/NF-kB and activating p38 MAPK.^90,91

An in vitro research by Michalak et al on the effectiveness of salinomycin and its derivatives in overcoming platinum drug resistance in ovarian most cancers revealed that salinomycin and its derivatives, together with the extensively used anticancer medication 5-fluorouracil, gemcitabine, and cisplatin, can considerably overcome platinum drug resistance in sufferers with ovarian most cancers. The research additionally means that combining salinomycin with anticancer drugs like gemcitabine or 5-fluorouracil could present new therapy choices for sufferers with ovarian most cancers.92 Equally, a research discovered that the mixture of salinomycin and paclitaxel additionally enhanced the inhibition of ovarian most cancers stem cells.⁸¹

Nigericin

Nigericin is an acid polyether potassium ion service antibiotic, which is extensively used within the therapy of hen coccidiosis. In 2009, it was first reported that nigericin has a cytotoxic impact on breast most cancers tumor stem cells. In 2011, the College of California, USA, confirmed utilizing the HEK293 cell line that nigericin can selectively inhibit the Wnt signaling pathway at nanomolar focus ranges. In 2012, researchers from Shanghai Jiao Tong College confirmed that nigericin can inhibit colorectal most cancers metastasis by affecting epithelial-mesenchymal transition. On the similar time, ovarian most cancers cells are considerably inhibited by nigericin. When it comes to stopping tumor cell metastasis and invasion, Wang et al used two ovarian most cancers cell traces, A2780 and SKOV3, to look at the mechanism and inhibitory impact of nigericin on human epithelial ovarian most cancers cells. The research discovered that nigericin can have an effect on EMT by regulating the Wnt/β-catenin signaling pathway, thereby inhibiting the proliferation, migration, and invasion means of epithelial ovarian most cancers, and having a particular perform in stopping the angiogenesis of ovarian epithelial most cancers cells.⁹³

In keeping with analysis, nigericin could also be a novel chemotherapeutic candidate for epithelial ovarian most cancers. Zhou et al performed additional analysis on the consequences and potential mechanisms of the mixture chemotherapy of nigericin and cisplatin on epithelial ovarian most cancers. Analysis has discovered that the inhibitory impact of cisplatin on the migration and colony formation of epithelial ovarian most cancers cells could be strengthened when nigericin and cisplatin are mixed. The mechanism could also be attributable to nigericin inhibiting slug expression by selling slug-like ubiquitination modification and inhibiting the Wnt/β-catenin signaling pathway from being activated.⁹⁴ Nissin has an advantageous affect on the expansion and metastasis of ovarian most cancers cells, whether or not it’s employed alone or at the side of cisplatin, and will enhance the result of ovarian most cancers therapy.

Conclusion

Ovarian most cancers has a excessive recurrence charge and poor prognosis, posing a major risk to ladies’s well being. Creating new drugs is important for treating ovarian most cancers. The potential of ion-carrier antibiotics in anti-tumor remedy is steadily being acknowledged, and so they have proven some promise in ovarian most cancers therapy. Total, the usage of ionophore antibiotics for ovarian most cancers remains to be not effectively understood. Additional experiments are wanted to discover their software and therapeutic mechanisms, which may result in progressive approaches and insights for growing new remedies for ovarian most cancers.

Abbreviations

EGFR, Epidermal progress issue receptor; TRAIL, Tumor necrosis factor-related apoptosis-induced ligand; EMT, Epithelial-mesenchymal transition; PDAC, Pancreatic ductal adenocarcinoma.

Writer Contributions

All authors made a major contribution to the work reported, whether or not that’s within the conception, research design, execution, acquisition of knowledge, evaluation and interpretation, or in all these areas; took half in drafting, revising or critically reviewing the article; gave last approval of the model to be printed; have agreed on the journal to which the article has been submitted; and conform to be accountable for all points of the work.

Funding

Pure Science Basis of Shandong Province (ZR2023M380); Zaozhuang Expertise Aggregation Program Particular Fund.

Disclosure

The authors declare that the analysis was performed within the absence of any business or monetary relationships that could possibly be construed as a possible battle of curiosity.

References

1. Sung H, Ferlay J, Siegel RL, et al. World most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660

2. Sasamoto N, Elias KM. Early detection of ovarian most cancers. Chilly Spring Harb Perspect Med. 2023;13(11):a041337. doi:10.1101/cshperspect.a041337

3. Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for ovarian most cancers: adjuvant, mixture, and neoadjuvant. Entrance Immunol. 2020;11:577869. doi:10.3389/fimmu.2020.577869

4. Liu HD, Xia BR, Jin MZ, Lou G. Organoid of ovarian most cancers: genomic evaluation and drug screening. Clin Transl Oncol. 2020;22(8):1240–1251. doi:10.1007/s12094-019-02276-8

5. Arnaoutoglou C, Dampala Okay, Anthoulakis C, et al. Epithelial ovarian most cancers: a 5 12 months assessment. Medicina. 2023;59(7):1183. doi:10.3390/medicina59071183

6. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the worldwide most cancers incidence and mortality in 2018: GLOBOCAN sources and strategies. Int J Most cancers. 2019;144(8):1941–1953. doi:10.1002/ijc.31937

7. Richardson DL, Eskander RN, O’Malley DM. Advances in ovarian most cancers care and unmet therapy wants for sufferers with platinum resistance: a story assessment. JAMA Oncol. 2023;9(6):851–859. doi:10.1001/jamaoncol.2023.0197

8. Rufián S, Muñoz-Casares FC, Briceño J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the therapy of peritoneal carcinomatosis in recurrent or major ovarian most cancers. J Surg Oncol. 2006;94(4):316–324. doi:10.1002/jso.20597

9. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Latest developments of most cancers in Europe: a mixed method of incidence, survival and mortality for 17 most cancers websites because the Nineteen Nineties. Eur J Most cancers. 2008;44(10):1345–1389. doi:10.1016/j.ejca.2007.12.015

10. De Angelis R, Sant M, Coleman MP, et al. Most cancers survival in Europe 1999-2007 by nation and age: outcomes of EUROCARE–5-a population-based research. Lancet Oncol. 2014;15(1):23–34. doi:10.1016/S1470-2045(13)70546-1

11. Ottevanger PB. Ovarian most cancers stem cells extra questions than solutions. Semin Most cancers Biol. 2017;44:67–71. doi:10.1016/j.semcancer.2017.04.009

12. de Vries G, Rosas-Plaza X, van Vugt M, Gietema JA, de Jong S. Testicular most cancers: determinants of cisplatin sensitivity and novel therapeutic alternatives. Most cancers Deal with Rev. 2020;88:102054. doi:10.1016/j.ctrv.2020.102054

13. Leon LM, Gautier M, Allan R, et al. Correction: the nuclear hypoxia-regulated NLUCAT1 lengthy non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma via regulation of oxidative stress. Oncogene. 2021;40(14):2621. doi:10.1038/s41388-021-01670-3

14. Wu X, Zhao J, Ruan Y, Solar L, Xu C, Jiang H. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian most cancers. Cell Demise Dis. 2018;9(11):1102. doi:10.1038/s41419-018-1101-0

15. Wang Y, Chiou YS, Chong QY, et al. Pharmacological inhibition of BAD Ser99 phosphorylation enhances the efficacy of cisplatin in ovarian most cancers by inhibition of most cancers stem cell-like habits. ACS Pharmacol Transl Sci. 2020;3(6):1083–1099. doi:10.1021/acsptsci.0c00064

16. Alraouji NN, Al-Mohanna FH, Ghebeh H, et al. Tocilizumab potentiates cisplatin cytotoxicity and targets most cancers stem cells in triple-negative breast most cancers. Mol Carcinog. 2020;59(9):1041–1051. doi:10.1002/mc.23234

17. Liu L, Meng T, Zheng X, et al. Transgelin 2 promotes paclitaxel resistance, migration, and invasion of breast most cancers by straight interacting with PTEN and activating PI3K/Akt/GSK-3β pathway. Mol Most cancers Ther. 2019;18(12):2457–2468. doi:10.1158/1535-7163.MCT-19-0261

18. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as first-line upkeep in Ovarian most cancers. New Engl J Med. 2019;381(25):2416–2428. doi:10.1056/NEJMoa1911361

19. Markowska A, Kaysiewicz J, Markowska J, Huczyński A. Doxycycline, salinomycin, monensin and ivermectin repositioned as most cancers medication. Bioorg Med Chem Lett. 2019;29(13):1549–1554. doi:10.1016/j.bmcl.2019.04.045

20. Mollenhauer HH, James Morré D, Rowe LD. Alteration of intracellular visitors by monensin; mechanism, specificity and relationship to toxicity. BBA. 1990;1031(2):225–246. doi:10.1016/0304-4157(90)90008-Z

21. Antoszczak M, Steverding D, Huczyński A. Anti-parasitic exercise of polyether ionophores. Eur J Med Chem. 2019;166:32–47. doi:10.1016/j.ejmech.2019.01.035

22. Gu J, Huang L, Zhang Y. Monensin inhibits proliferation, migration, and promotes apoptosis of breast most cancers cells through downregulating UBA2. Drug Dev Res. 2020;81(6):745–753. doi:10.1002/ddr.21683

23. Xin H, Li J, Zhang H, et al. Monensin could inhibit melanoma by regulating the choice between differentiation and stemness of melanoma stem cells. PeerJ. 2019;7:e7354.

24. Mohan CD, Rangappa S, Nayak SC, et al. Micro organism as a treasure home of secondary metabolites with anticancer potential. Semin Most cancers Biol. 2022;86(Pt 2):998–1013. doi:10.1016/j.semcancer.2021.05.006

25. Mai TT, Hamaï A, Hienzsch A, et al. Salinomycin kills most cancers stem cells by sequestering iron in lysosomes. Nat Chem. 2017;9(10):1025–1033. doi:10.1038/nchem.2778

26. Xu Z, Gao G, Liu F, et al. Molecular screening for nigericin therapy in pancreatic most cancers by high-throughput RNA sequencing. Entrance Oncol. 2020;10:1282. doi:10.3389/fonc.2020.01282

27. Ingham AC, Pamp SJ. Mucosal microbiotas and their function in stem cell transplantation. Apmis. 2022;130(12):741–750. doi:10.1111/apm.13208

28. Ali I, Alfarouk KO, Reshkin SJ, Ibrahim ME. Doxycycline as potential anti-cancer agent. Anticancer Brokers Med Chem. 2017;17(12):1617–1623. doi:10.2174/1871520617666170213111951

29. Zhang L, Xu L, Zhang F, Vlashi E. Doxycycline inhibits the most cancers stem cell phenotype and epithelial-to-mesenchymal transition in breast most cancers. Cell Cycle. 2017;16(8):737–745. doi:10.1080/15384101.2016.1241929

30. Butters C, Thursky Okay, Hanna DT, et al. Antagonistic results of antibiotics in kids with most cancers: are short-course antibiotics for febrile neutropenia a part of the answer? Professional Rev Anti Infect Ther. 2023;21(3):267–279. doi:10.1080/14787210.2023.2171987

31. Dominguez-Gomez G, Chavez-Blanco A, Medina-Franco JL, et al. Ivermectin as an inhibitor of most cancers stem‑like cells. Mol Med Rep. 2018;17(2):3397–3403. doi:10.3892/mmr.2017.8231

32. Huczyński A. Polyether ionophores—promising bioactive molecules for most cancers remedy. Bioorg Med Chem Lett. 2012;22(23):7002–7010. doi:10.1016/j.bmcl.2012.09.046

33. Wang X, Wu X, Zhang Z, et al. Monensin inhibits cell proliferation and tumor progress of chemo-resistant pancreatic most cancers cells by concentrating on the EGFR signaling pathway. Sci Rep. 2018;8(1):17914. doi:10.1038/s41598-018-36214-5

34. Wan W, Zhang X, Huang C, et al. Monensin inhibits glioblastoma angiogenesis through concentrating on a number of progress issue receptor signaling. Biochem Biophys Res Commun. 2020;530(2):479–484. doi:10.1016/j.bbrc.2020.05.057

35. Kim SH, Kim KY, Yu SN, et al. Monensin induces PC-3 prostate most cancers cell apoptosis through ROS manufacturing and Ca2+ homeostasis disruption. Anticancer Res. 2016;36(11):5835–5843. doi:10.21873/anticanres.11168

36. Park WH, Kim ES, Kim BK, Lee YY. Monensin-mediated progress inhibition in NCI-H929 myeloma cells through cell cycle arrest and apoptosis. Int J Oncol. 2003;23(1):197–204.

37. Park WH, Kim ES, Jung CW, Kim BK, Lee YY. Monensin-mediated progress inhibition of SNU-C1 colon most cancers cells through cell cycle arrest and apoptosis. Int J Oncol. 2003;22(2):377–382.

38. Choi HS, Jeong EH, Lee TG, et al. Autophagy inhibition with monensin enhances cell cycle arrest and apoptosis induced by mTOR or epidermal progress issue receptor inhibitors in lung most cancers cells. Tuberc Respir Dis. 2013;75(1):9–17. doi:10.4046/trd.2013.75.1.9

39. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of most cancers stem cells by high-throughput screening. Cell. 2009;138(4):645–659. doi:10.1016/j.cell.2009.06.034

40. Tang L, Duan W, Zhang C, et al. Potent salinomycin C20-O-alkyl oxime by-product SAL-98 effectively inhibits tumor progress and metastasis by affecting Wnt/β-catenin sign pathway. Biochem Pharmacol. 2023;214:115666. doi:10.1016/j.bcp.2023.115666

41. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in power lymphocytic leukemia cells. Proc Natl Acad Sci. 2011;108(32):13253–13257. doi:10.1073/pnas.1110431108

42. Tumova L, Pombinho AR, Vojtechova M, et al. Monensin inhibits canonical Wnt signaling in human colorectal most cancers cells and suppresses tumor progress in a number of intestinal neoplasia mice. Mol Most cancers Ther. 2014;13(4):812–822. doi:10.1158/1535-7163.MCT-13-0625

43. Zhou P, Li Y, Li B, et al. NMIIA promotes tumor progress and metastasis by activating the Wnt/β-catenin signaling pathway and EMT in pancreatic most cancers. Oncogene. 2019;38(27):5500–5515. doi:10.1038/s41388-019-0806-6

44. Vu T, Datta PK. Regulation of EMT in colorectal most cancers: a offender in metastasis. Cancers. 2017;9(12):171. doi:10.3390/cancers9120171

45. Yilmaz M, Christofori G. EMT, the cytoskeleton, and most cancers cell invasion. Most cancers Metastasis Rev. 2009;28(1–2):15–33. doi:10.1007/s10555-008-9169-0

46. Pastushenko I, Blanpain C. EMT transition states throughout tumor development and metastasis. Traits Cell Biol. 2019;29(3):212–226. doi:10.1016/j.tcb.2018.12.001

47. Ray I, Michael A, Meira LB, Ellis PE. The function of cytokines in epithelial-mesenchymal transition in gynaecological cancers: a scientific assessment. Cells. 2023;12(3):416. doi:10.3390/cells12030416

48. Vanneste M, Huang Q, Li M, et al. Excessive content material screening identifies monensin as an EMT-selective cytotoxic compound. Sci Rep. 2019;9(1):1200. doi:10.1038/s41598-018-38019-y

49. Pádua D, Barros R, Amaral AL, et al. A SOX2 reporter system identifies gastric most cancers stem-like cells delicate to monensin. Cancers. 2020;12(2):495. doi:10.3390/cancers12020495

50. Lee SY, Jeong EK, Ju MK, et al. Induction of metastasis, most cancers stem cell phenotype, and oncogenic metabolism in most cancers cells by ionizing radiation. Mol Most cancers. 2017;16(1):10. doi:10.1186/s12943-016-0577-4

51. Chen T, You Y, Jiang H, Wang ZZ. Epithelial-mesenchymal transition (EMT): a organic course of within the improvement, stem cell differentiation, and tumorigenesis. J Cell Physiol. 2017;232(12):3261–3272. doi:10.1002/jcp.25797

52. Dong -T-T, Zhou H-M, Wang -L-L, Feng B, Lv B, Zheng M-H. Salinomycin selectively targets ‘CD133+’ cell subpopulations and reduces malignant traits in colorectal most cancers traces. Ann Surg Oncol. 2011;18(6):1797–1804. doi:10.1245/s10434-011-1561-2

53. Asik A, Ay NPO, Bagca BG, Caglar HO, Gunduz C, Avci CB. Mixture of salinomycin and AZD3463 reveals synergistic impact on lowering the viability of T98G glioblastoma cells. Anti-Most cancers Brokers Med Chem. 2020;20(18):2267–2273. doi:10.2174/1871520620666200721121517

54. Simizu S, Takada M, Umezawa Okay, Imoto M. Requirement of Caspase-3(-like) protease-mediated hydrogen peroxide manufacturing for apoptosis induced by numerous anticancer medication*. J Biol Chem. 1998;273(41):26900–26907. doi:10.1074/jbc.273.41.26900

55. Kawada M, Sumi S, Umezawa Okay, Inouye S, Sawa T, Seto H. Circumvention of multidrug resistance in human carcinoma KB cells by polyether antibiotics. J Antibiotics. 1992;45(4):556–562. doi:10.7164/antibiotics.45.556

56. Zhi QM, Chen XH, Ji J, et al. Salinomycin can successfully kill ALDHhigh stem-like cells on gastric most cancers. Biomed Pharmacother. 2011;65(7):509–515. doi:10.1016/j.biopha.2011.06.006

57. Kawada M, Umezawa Okay. Lengthy-lasting accumulation of vinblastine in inostamycin-treated multidrug-resistant KB cells. Jpn J Most cancers Res. 1991;82(10):1160–1164. doi:10.1111/j.1349-7006.1991.tb01771.x

58. Kawada M, Umezawa Okay. Inostamycin, an inhibitor of P-glycoprotein perform, interacts particularly with phosphatidylethanolamine. Jpn J Most cancers Res. 1995;86(9):873–878. doi:10.1111/j.1349-7006.1995.tb03099.x

59. Baba Y, Tsukuda M, Mochimatsu I, et al. Cytostatic impact of inostamycin, an inhibitor of cytidine 5′-Diphosphate 1,2-Diacyl-sn-Glycerol (CDP-DG): inositol transferase, on oral squamous cell carcinoma cell lineS. Cell Biol Int. 2001;25(7):613–620. doi:10.1006/cbir.2000.0706

60. Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM. Potent and particular antitumor results of an anti-CD22–focused cytotoxic ribonuclease: potential for the therapy of non-Hodgkin lymphoma. Blood. 2001;97(2):528–535. doi:10.1182/blood.V97.2.528

61. Wooden DJT, Rumsby MG, Warr JR. Monensin and verapamil don’t alter intracellular localisation of daunorubicin in multidrug resistant human KB cells. Most cancers Lett. 1996;108(1):41–47. doi:10.1016/S0304-3835(96)04368-6

62. Sehested M, Skovsgaard T, Roed H. The carboxylic ionophore monensin inhibits lively drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells. Biochem Pharmacol. 1988;37(17):3305–3310. doi:10.1016/0006-2952(88)90643-0

63. Tyagi M, Patro BS. Salinomycin reduces progress, proliferation and metastasis of cisplatin resistant breast most cancers cells through NF-kB deregulation. Toxicol In Vitro. 2019;60:125–133. doi:10.1016/j.tiv.2019.05.004

64. Yakisich JS, Azad N, Kaushik V, O’Doherty GA, Iyer AK. Nigericin decreases the viability of multidrug-resistant most cancers cells and lung tumorspheres and potentiates the consequences of cardiac glycosides. Tumour Biol. 2017;39(3):1010428317694310. doi:10.1177/1010428317694310

65. Jiang L, Wang P, Solar YJ, Wu YJ. Ivermectin reverses the drug resistance in most cancers cells via EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Most cancers Res. 2019;38(1):265. doi:10.1186/s13046-019-1251-7

66. Ochi Okay, Suzawa Okay, Tomida S, et al. Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based mixed remedy in non-small cell lung most cancers. Biochem Biophys Res Commun. 2020;529(3):760–765. doi:10.1016/j.bbrc.2020.06.077

67. Yoon MJ, Kang YJ, Kim IY, et al. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells through endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis. 2013;34(8):1918–1928. doi:10.1093/carcin/bgt137

68. Rajendran V, Ilamathi HS, Dutt S, Lakshminarayana TS, Ghosh PC. Chemotherapeutic potential of monensin as an anti-microbial agent. Curr Prime Med Chem. 2018;18(22):1976–1986. doi:10.2174/1568026619666181129141151

69. Dayekh Okay, Johnson-Obaseki S, Corsten M, et al. Monensin inhibits epidermal progress issue receptor trafficking and activation: synergistic cytotoxicity together with EGFR inhibitors. Mol Most cancers Ther. 2014;13(11):2559–2571. doi:10.1158/1535-7163.MCT-13-1086

70. Dai SY, Herrman TJ. Analysis of two liquid chromatography/tandem mass spectrometry platforms for quantification of monensin in animal feed and milk. Fast Commun Mass Spectrom. 2010;24(10):1431–1438. doi:10.1002/rcm.4533

71. Xiao X, Wang C, Chang D, et al. Identification of potent and secure antiviral therapeutic candidates in opposition to SARS-CoV-2. Entrance Immunol. 2020;11:586572. doi:10.3389/fimmu.2020.586572

72. Hu M, Zhang Y, Li X, et al. Alterations of endometrial epithelial-mesenchymal transition and MAPK signalling parts in ladies with PCOS are partially modulated by metformin in vitro. Mol Hum Reprod. 2020;26(5):312–326. doi:10.1093/molehr/gaaa023

73. Xin L, Zhao R, Lei J, et al. SND1 acts upstream of SLUG to control the epithelial-mesenchymal transition (EMT) in SKOV3 cells. FASEB j. 2019;33(3):3795–3806. doi:10.1096/fj.201801728R

74. Yao S, Wang W, Zhou B, Cui X, Yang H, Zhang S. Monensin suppresses cell proliferation and invasion in ovarian most cancers by enhancing MEK1 SUMOylation. Exp Ther Med. 2021;22(6):1390. doi:10.3892/etm.2021.10826

75. Deng Y, Zhang J, Wang Z, et al. Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian most cancers cells. Sci Rep. 2015;5:17523. doi:10.1038/srep17523

76. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883. doi:10.1038/onc.2011.384

77. Ghosh S. Cisplatin: the primary metallic primarily based anticancer drug. Bioorg Chem. 2019;88:102925. doi:10.1016/j.bioorg.2019.102925

78. van Zyl B, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian most cancers: what can we use to enhance therapy. Endocr Relat Most cancers. 2018;25(5):R303–r318. doi:10.1530/ERC-17-0336

79. Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy resistance in superior ovarian most cancers sufferers. Biomark Most cancers. 2019;11:1179299×19860815. doi:10.1177/1179299X19860815

80. An H, Kim JY, Lee N, Cho Y, Oh E, Search engine optimization JH. Salinomycin possesses anti-tumor exercise and inhibits breast most cancers stem-like cells through an apoptosis-independent pathway. Biochem Biophys Res Commun. 2015;466(4):696–703. doi:10.1016/j.bbrc.2015.09.108

81. Lee HG, Shin SJ, Chung HW, et al. Salinomycin reduces stemness and induces apoptosis on human ovarian most cancers stem cell. J Gynecol Oncol. 2017;28(2):e14. doi:10.3802/jgo.2017.28.e14

82. Mao J, Fan S, Ma W, et al. Roles of Wnt/β-catenin signaling within the gastric most cancers stem cells proliferation and salinomycin therapy. Cell Demise Dis. 2014;5(1):e1039. doi:10.1038/cddis.2013.515

83. Tang QL, Zhao ZQ, Li JC, et al. Salinomycin inhibits osteosarcoma by concentrating on its tumor stem cells. Most cancers Lett. 2011;311(1):113–121. doi:10.1016/j.canlet.2011.07.016

84. Li T, Su L, Zhong N, et al. Salinomycin induces cell dying with autophagy via activation of endoplasmic reticulum stress in human most cancers cells. Autophagy. 2013;9(7):1057–1068. doi:10.4161/auto.24632

85. Endo S, Nakata Okay, Sagara A, et al. Autophagy inhibition enhances antiproliferative impact of salinomycin in pancreatic most cancers cells. Pancreatology. 2017;17(6):990–996. doi:10.1016/j.pan.2017.08.009

86. Kim KY, Park KI, Kim SH, et al. Salinomycin induces reactive oxygen species and apoptosis in aggressive breast most cancers cells as mediated with regulation of autophagy. Anticancer Res. 2017;37(4):1747–1758.

87. Markowska A, Sajdak S, Markowska J, Huczyński A. Angiogenesis and most cancers stem cells: new views on remedy of ovarian most cancers. Eur J Med Chem. 2017;142:87–94. doi:10.1016/j.ejmech.2017.06.030

88. Li R, Dong T, Hu C, Lu J, Dai J, Liu P. Salinomycin repressed the epithelial-mesenchymal transition of epithelial ovarian most cancers cells through downregulating Wnt/β-catenin pathway. Onco Targets Ther. 2017;10:1317–1325. doi:10.2147/OTT.S126463

89. Kaplan F, Teksen F. Apoptotic results of salinomycin on human ovarian most cancers cell line (OVCAR-3). Tumor Biol. 2016;37(3):3897–3903. doi:10.1007/s13277-015-4212-6

90. Parajuli B, Lee H-G, Kwon S-H, et al. Salinomycin inhibits Akt/NF-κB and induces apoptosis in cisplatin resistant ovarian most cancers cells. Most cancers Epidemiol. 2013;37(4):512–517. doi:10.1016/j.canep.2013.02.008

91. Zhang B, Wang X, Cai F, Chen W, Loesch U, Zhong XY. Antitumor properties of salinomycin on cisplatin-resistant human ovarian most cancers cells in vitro and in vivo: involvement of p38 MAPK activation. Oncol Rep. 2013;29(4):1371–1378. doi:10.3892/or.2013.2241

92. Michalak M, Lach MS, Antoszczak M, Huczyński A, Suchorska WM. Overcoming resistance to platinum-based medication in ovarian most cancers by salinomycin and its derivatives—an in vitro research. Molecules. 2020;25(3):537. doi:10.3390/molecules25030537

93. Wang W, Zhao Y, Yao S, et al. Nigericin inhibits epithelial ovarian most cancers metastasis by suppressing the cell cycle and epithelial-mesenchymal transition. Biochem Biokhimiia. 2017;82(8):933–941. doi:10.1134/S0006297917080089

94. Zhou B, Wang C, Liu X, et al. Mixture of nigericin with cisplatin enhances the inhibitory impact of cisplatin on epithelial ovarian most cancers metastasis by inhibiting slug expression through the Wnt/β-catenin signalling pathway. Oncol Lett. 2021;22(4):700. doi:10.3892/ol.2021.12961